NanoViricides, Inc.
$1.28
▼
-2.55%
2026-04-21 08:26:01
www.nanoviricides.com
ASE: NNVC
Explore NanoViricides, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$29.59 M
Current Price
$1.28
52W High / Low
$2.23 / $0.85
Stock P/E
—
Book Value
$0.51
Dividend Yield
—
ROCE
-127.59%
ROE
-77.53%
Face Value
—
EPS
$-0.49
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
1.3
Debt / Equity
—
Current Ratio
4.43
Quick Ratio
1.28
Forward P/E
-2.81
Price / Sales
—
Enterprise Value
$16.07 M
EV / EBITDA
-2.07
EV / Revenue
—
Rating
None
Target Price
$6.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
| 2. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 3. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 4. | Rallybio Corporation | $8.29 | — | $43.48 M | — | -56.97% | -15.01% | $11.49 / $1.9 | $10.97 |
| 5. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 6. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 7. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.23 M | -1.8 M | -2.12 M | -2.25 M | -2.06 M | — |
| Net Profit | -2.22 M | -1.79 M | -2.1 M | -2.22 M | -2.03 M | — |
| EPS in Rs | -0.1 | -0.08 | -0.1 | -0.1 | -0.09 | -0.23 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -9.59 M | -8.52 M | -8.94 M | -8.11 M |
| Net Profit | -9.47 M | -8.29 M | -8.59 M | -8.11 M |
| EPS in Rs | -0.44 | -0.38 | -0.4 | -0.38 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.82 M | 12.82 M | 16.9 M | 23.49 M |
| Total Liabilities | 1.31 M | 1.36 M | 2.03 M | 0.41 M |
| Equity | 7.52 M | 11.46 M | 14.87 M | 23.08 M |
| Current Assets | 1.67 M | 4.97 M | 8.45 M | 14.42 M |
| Current Liabilities | 1.31 M | 1.36 M | 0.53 M | 0.41 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.48 M | -6.32 M | -5.67 M | -5.89 M |
| Investing CF | -0.06 M | -0.16 M | -0.15 M | -0.32 M |
| Financing CF | 5.3 M | 3.12 M | -0.09 M | -0.23 M |
| Free CF | -8.54 M | -6.47 M | -5.82 M | -6.22 M |
| Capex | -0.06 M | -0.16 M | -0.15 M | -0.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 3.43% | -5.94% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.